![Hands doing a puzzle.](/find-studies/sites/default/files/styles/page_banner/public/banners/B%20puzzle%202%20-%20home.png?h=0bfc658d&itok=BAOHNn7S)
The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
60+
Diagnosis of Alzheimer's disease
Must have a study partner
It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.
You are eligible to participate if you meet the following criteria:
• Age ≥ 55; females must be post-menopausal
• DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)
• sMMSE ≤ 24
• Clinically significant agitation based on IPA definition
• Stable cognition-enhancing medication for at least 3 months prior to study enrolment
• Availability of a caregiver to accompany participant to study visits and to participate in the study
• Ability to speak English
Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.
Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.
Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.
Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.
Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.
Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.
Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.
Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.
Have not undergone any significant head trauma or surgery in the past 6 months.
Are not pregnant or planning to become pregnant during the duration of the study.
Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.
Ability to speak English and French
This study, "Stranger than Family: Decision-Making & Ethics of Substitution for People Living With
Dementia Going It Alone", explores how people facing dementia alone are connected with a substitute
decision-maker and how ideas about capacity, consent, and decision-making affect them.
Interviews will be conducted with:
- People who are facing dementia alone
- Healthcare and social service workers
- Substitute decision-makers for others who are not close family members or close friends
The overall goal of this study is to identify opportunities for advocacy, policy, and practice change to
better support people facing dementia alone.
You are eligible to participate if you:
- Live in Ontario or Alberta AND
- Have a diagnosis of dementia or are at-risk and planning for a future living with dementia and are
facing dementia alone OR
- Are a healthcare or social service worker, or other professional who has experience trying to connect
adult clients with a substitute decision-maker OR
- Have experience as a substitute decision-maker for someone living with dementia who is not a close
family member or friend
In addition, to be eligible you must:
- Be able to participate in an interview over the phone, on Zoom, or in-person AND
- Understand the purpose of the study and what participation involves
-Speak English
VRx@Home is a 5-week virtual reality at-home intervention with the goal to explore whether virtual reality experiences can enhance communication between persons living with dementia and their care partners. We also aim to explore how a head-mounted VR system, which delivers a fully immersive experience compares to a Tablet-based technology.
The study is aiming to assess whether nutritional intervention with personalized, preselected prebiotics can affect cognitive function in those with Alzheimer’s disease. This study is placebo-controlled, and participants will be randomized to either the placebo or prebiotic.
We want to determine if a nutrition questionnaire (SCREEN) works well to identify nutrition challenges for older adults with diagnosed memory problems, cognitive impairment or dementia when completed by themselves, or by a care partner on behalf of their cared for person.
You may be eligible if you are:
• 55 years or older
• Read/speak English
• Live within 45km of Waterloo, Guelph or London.
AND are an:
• Older adult with diagnosed memory problems, cognitive impairment or dementia with a care partner who either lives with you, or who is in daily contact with you and would be able to support reporting of their eating behaviours
• If living in a retirement home, the older adult must have lived in their home for at least 3 months and receive 2 or more meals each day from their retirement home
The purpose of this phase 2 study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Follow us: